Amneal Pharmaceuticals (AMRX)

NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-23

$20.38-0.49%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Amneal Pharmaceuticals’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	823.84M
EPS	—	0.223
FY 2026 · Annual
Revenue	$3.1B–$3.2B	3.16B
EPS	$0.96–$1.06non-GAAP	1.027
Capital expenditure	About $150M	—
EBITDA	$750M–$780Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	3.45B
EPS	—	1.204

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash from operations improves from negative $26.7 million	A primary condition in Amneal Pharmaceuticals's published investment case. The stated target is Cash flow from operations >= $0 million.	Broken	Cash flow remains negative below zero over next 4 quarters	Cash from operations: $-19.262M FY2026-Q2; GAAP. Published target: Cash flow from operations >= $0 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-19,262,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful expansion through acquisition of Kashiv BioSciences	The company expands by buying Kashiv BioSciences.	Improving	Acquisition fails or does not contribute to growth by FY26	Qualitative: Acquisition closed 2026-08-10; FDA approval & raised FY26 guidance Kashiv acquisition closed 2026-08-10. FDA approval for Lanreotide and raised FY26 guidance support successful integration and growth. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 disclosures including 2026-Q2 and two 2026-08 filings. Management completed the acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars platform to capitalize on a $300B+ global biologics loss-of-exclusivity wave. This strategic M&A expands Amneal's growth profile into the 2030s. The transaction includes $375M cash, $375M equity, and up to $350M in milestone payments. The trajectory is delivering with the acquisition completed as planned. Delivery assessment Oct 24, 2026
Operating income improves to at least $141.8 million in Q1 2026	A primary condition in Amneal Pharmaceuticals's published investment case. The stated target is >= $141.8 million.	Intact	Operating income falls below $130 million in Q1 2026	Operating income: $129.769M FY2026-Q2; GAAP. Published target: >= $141.8 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026129,769,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 582a0cc4-a15d-4421-b56f-3856ee4da318. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue grows to at least $3.05 billion in 2026	Amneal grows revenue about 6% a year to $3.1 billion in 2026.	Intact	Revenue falls below $3.0 billion in FY26	Revenue: $796.197M FY2026-Q2; GAAP. Published target: >= $3.05 billion. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026796,197,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 582a0cc4-a15d-4421-b56f-3856ee4da318. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 disclosures including 2026-Q2 and two 2026-08 filings. Management completed the acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars platform to capitalize on a $300B+ global biologics loss-of-exclusivity wave. This strategic M&A expands Amneal's growth profile into the 2030s. The transaction includes $375M cash, $375M equity, and up to $350M in milestone payments. The trajectory is delivering with the acquisition completed as planned. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$1.12 → Unavailable · observed estimates

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.12	Unavailable	5 / 4
2026-07-25	$1.12	Unavailable	5 / 4
2026-07-26	$1.12	Unavailable	5 / 4
2026-07-27	Unavailable	Unavailable	2 / 3
2026-07-28	$1.12	Unavailable	5 / 4
2026-07-29	$1.12	Unavailable	5 / 4
2026-07-30	$1.12	Unavailable	5 / 4
2026-07-31	$1.12	Unavailable	5 / 4
2026-08-01	$1.16	Unavailable	5 / 4
2026-08-02	$1.16	Unavailable	5 / 4
2026-08-03	$1.16	Unavailable	5 / 4
2026-08-04	$1.16	Unavailable	5 / 4
2026-08-05	$1.18	Unavailable	5 / 4
2026-08-06	$1.18	Unavailable	5 / 4
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	$1.18	Unavailable	5 / 4
2026-08-09	$1.18	Unavailable	5 / 4
2026-08-10	$1.18	Unavailable	5 / 4
2026-08-11	Unavailable	Unavailable	2 / 3
2026-08-12	$1.18	Unavailable	5 / 4
2026-08-13	$1.18	Unavailable	5 / 4
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	2 / 3
2026-08-22	Unavailable	Unavailable	2 / 3
2026-08-23	Unavailable	Unavailable	2 / 3
2026-08-24	Unavailable	Unavailable	2 / 3
2026-08-25	Unavailable	Unavailable	2 / 3
2026-08-26	Unavailable	Unavailable	2 / 3
2026-08-27	Unavailable	Unavailable	2 / 3
2026-08-28	Unavailable	Unavailable	2 / 3
2026-08-29	Unavailable	Unavailable	2 / 3
2026-08-30	Unavailable	Unavailable	2 / 3
2026-08-31	Unavailable	Unavailable	2 / 3
2026-09-01	Unavailable	Unavailable	2 / 3
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	3 / 3
2026-09-13	Unavailable	Unavailable	3 / 3
2026-09-14	Unavailable	Unavailable	3 / 3
2026-09-15	Unavailable	Unavailable	3 / 3
2026-09-16	Unavailable	Unavailable	3 / 3
2026-09-17	Unavailable	Unavailable	3 / 3
2026-09-18	Unavailable	Unavailable	3 / 3
2026-09-19	Unavailable	Unavailable	3 / 3
2026-09-20	Unavailable	Unavailable	3 / 3
2026-09-21	Unavailable	Unavailable	3 / 3
2026-09-22	Unavailable	Unavailable	3 / 3
2026-09-23	Unavailable	Unavailable	3 / 3
2026-09-24	Unavailable	Unavailable	3 / 3
2026-09-25	Unavailable	Unavailable	3 / 4
2026-09-26	Unavailable	Unavailable	3 / 4
2026-09-27	Unavailable	Unavailable	3 / 4
2026-09-28	Unavailable	Unavailable	3 / 4
2026-09-29	Unavailable	Unavailable	3 / 4
2026-09-30	Unavailable	Unavailable	3 / 4
2026-10-01	Unavailable	Unavailable	3 / 4
2026-10-02	Unavailable	Unavailable	3 / 4
2026-10-03	Unavailable	Unavailable	3 / 4
2026-10-04	Unavailable	Unavailable	3 / 4
2026-10-05	Unavailable	Unavailable	3 / 4
2026-10-06	Unavailable	Unavailable	3 / 4
2026-10-07	Unavailable	Unavailable	3 / 4
2026-10-08	Unavailable	Unavailable	3 / 4
2026-10-09	Unavailable	Unavailable	3 / 4
2026-10-10	Unavailable	Unavailable	3 / 4
2026-10-11	Unavailable	Unavailable	3 / 4
2026-10-12	Unavailable	Unavailable	3 / 4
2026-10-13	Unavailable	Unavailable	3 / 4
2026-10-14	Unavailable	Unavailable	3 / 4
2026-10-15	Unavailable	Unavailable	3 / 4
2026-10-16	Unavailable	Unavailable	3 / 4
2026-10-17	Unavailable	Unavailable	3 / 4
2026-10-18	Unavailable	Unavailable	3 / 4
2026-10-19	Unavailable	Unavailable	3 / 4
2026-10-20	Unavailable	Unavailable	3 / 4
2026-10-21	Unavailable	Unavailable	3 / 4
2026-10-22	Unavailable	Unavailable	3 / 4
2026-10-23	Unavailable	Unavailable	3 / 4
2026-10-24	Unavailable	Unavailable	3 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	5	0	0
2026-07-01	4	0	0
2026-08-01	5	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash from operations improves from negative $26.7 millionPublished status: Broken
Operating income improves to at least $141.8 million in Q1 2026Operating income: $129.769M
Revenue grows to at least $3.05 billion in 2026Revenue: $796.197M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.2%Typical daily move · historical

Downside history

-22.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Amneal Pharmaceuticals outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth and execution story in pharmaceuticals, supported by improving results and an expanded biosimilars business. The long-term thesis is intact, but earnings quality is still classified as loss-making and the evidence has medium confidence.

What's priced into Amneal Pharmaceuticals

AMRX is valued at a sizable premium to peers, and the evidence describes its valuation as expensive. The market appears to recognize the recent execution and growth prospects, with only a modest expectations gap; pricing is tagged as justified, with low fragility.

What the fundamentals likely do

Near-term results have been strong: management raised 2026 revenue and adjusted EBITDA guidance, and revenue, operating income, and net income improved in the reported periods. The Kashiv BioSciences acquisition is complete, adding a biosimilars platform, while the main near-term risk is a reversal in guidance; the snapshot also notes a history of a deep miss in a high-miss-rate industry.

What Amneal Pharmaceuticals hinges on

Over the next one to three years, the thesis hinges on continued delivery against raised guidance and on turning the Kashiv acquisition into durable growth. A guidance cut would damage credibility, while weaker employment data could weigh on cyclical healthcare names; continued earnings strength among sector peers would support the sector backdrop.